TrialCompass™ TCL
Back to trials
Phase 2RecruitingPriority 2 · High priorityNCT06534060

MB-105 in Patients With CD5 Positive T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is testing Genetic: MB-105 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 12 locations in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Genetic: MB-105 (BIOLOGICAL): MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.

  • MB-105

    Genetic

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

MB-105 in Patients With CD5 Positive T-cell Lymphoma

NCT06534060

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This trial is testing Genetic: MB-105 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 12 locations in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

What's being tested

Genetic: MB-105 (BIOLOGICAL): MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.

Drugs / treatments: Genetic: MB-105

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 46 patients

Primary endpoint: Adverse events (AEs) per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; Objective response rate (ORR)

Ages: 18 Years to —

Start date: 2025-02-15 | Est. completion: 2029-12

Locations

12 US sites · 12 total

California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina, Ohio, Oregon, Texas

Contact

Federica Giordano, Ph.D. | clinicaltrials@march.bio | 7138980838

Sponsor: March Biosciences Inc (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06534060

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.